Integrated Biopharma, Inc. INBP
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -667.42% | -236.99% | -756.90% | -52.51% | -166.42% |
| Total Depreciation and Amortization | 14.37% | 17.11% | 4.09% | 2.19% | 3.15% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -30.56% | -159.69% | -158.40% | -52.57% | 514.39% |
| Change in Net Operating Assets | -92.96% | 306.82% | 413.13% | 517.71% | 54.73% |
| Cash from Operations | -302.03% | -16.07% | 206.97% | 98.02% | 417.74% |
| Capital Expenditure | -1,590.00% | 100.00% | 17.24% | -208.93% | 106.85% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -3,625.00% | 105.17% | 17.24% | -208.93% | 97.26% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1,100.00% | -- | -- | -57.14% | 90.91% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -117.91% | -- | -161.11% | -57.14% | 709.09% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -307.19% | 2.40% | 206.32% | 88.05% | 290.67% |